On this page
GTP cyclohydrolase deficiency (Segawa disease)
This inherited disorder typically presents in early childhood with involuntary muscle contractions and stiffness that often fluctuate throughout the day. It is caused by changes in the GCH1 gene, leading to a shortage of important neurotransmitters in the brain.
Available at Jeen Health
Clinical tests that include this
Overview
GTP cyclohydrolase deficiency (GCH1-deficient Dopa-Responsive Dystonia, or DRD) is a rare, inherited neurological disorder characterised by involuntary muscle movements and stiffness, known as dystonia. Symptoms typically begin in childhood, often between ages one and ten, and can vary in severity. A key feature of this condition is its response to low doses of levodopa, a medication that can significantly improve symptoms, sometimes leading to complete resolution [PMID:16489370].
Unlike many other forms of dystonia, the symptoms of GCH1-deficient DRD tend to be worse in the evenings and after physical activity, often improving significantly after sleep. It affects individuals globally, and while specific prevalence figures are not well established, it is considered a rare disease within the UK population and worldwide.
Symptoms & clinical features
The primary symptom of GCH1-deficient DRD is dystonia, which involves sustained or intermittent muscle contractions causing abnormal, often repetitive, movements and postures. In affected children, this typically first appears in the legs, leading to difficulties with walking, such as toe-walking or a tendency to stumble [PMID:16489370].
Symptoms often worsen as the day progresses and may improve after rest or sleep. Other motor symptoms can include slowness of movement (bradykinesia), rigidity, and tremor, resembling features seen in Parkinson's disease. Less commonly, individuals might experience non-motor symptoms such as sleep disturbances or mild mood changes, though these are not primary features.
Video: Genetics 101
Affected organs
GCH1-deficient DRD primarily affects the nervous system, specifically the parts of the brain responsible for controlling movement. The deficiency in tetrahydrobiopterin (BH4) and subsequent reduction in neurotransmitters like dopamine impact the basal ganglia, a group of structures deep within the brain involved in coordinating movement. While the physical manifestations are in the muscles, the underlying issue lies within the brain's neurochemical balance.
Risks & severity
The severity of GCH1-deficient DRD can vary, even within the same family. Without appropriate treatment, the dystonia can become progressively debilitating, significantly affecting mobility and quality of life. However, one of the defining characteristics of this condition is its excellent response to levodopa medication, which, when started early, can lead to substantial improvement and, in some cases, near-normal motor function [PMID:16489370].
Complications generally arise from untreated or late-diagnosed disease, leading to contractures (permanent shortening of muscles or tendons) or skeletal deformities due to prolonged abnormal postures. However, with timely diagnosis and consistent treatment, the long-term outlook is generally very positive, and life expectancy is typically not affected.
Genetic causes
GTP cyclohydrolase deficiency is caused by pathogenic changes in the GCH1 gene. This gene provides instructions for making an enzyme called GTP cyclohydrolase 1. This enzyme is crucial for the first step in the production of tetrahydrobiopterin (BH4) [PMID:33678082].
BH4 acts as an essential cofactor for several enzymes, including those involved in the synthesis of neurotransmitters such as dopamine and serotonin. Pathogenic variants in GCH1 lead to a reduced amount of functional GTP cyclohydrolase 1, resulting in a deficiency of BH4. This in turn reduces the production of dopamine in the brain, which is vital for smooth and coordinated movement. This dopamine deficiency is why the condition responds well to levodopa, a precursor to dopamine.
- GCH1 GTP cyclohydrolase 1The GCH1 gene provides instructions for producing GTP cyclohydrolase 1, an enzyme essential for synthesising tetrahydrobiopterin (BH4), a co-factor vital for neurotransmitter production.
Inheritance pattern
GTP cyclohydrolase deficiency is inherited in an autosomal dominant pattern. This means that a person needs to inherit only one altered copy of the GCH1 gene from a parent to develop the condition. If one parent has a pathogenic variant in GCH1, there is a 50% chance with each pregnancy that their child will inherit the altered gene and therefore be affected.
It is possible for a person to develop the condition without a family history if the genetic change occurs for the first time in them (a de novo variant). Family members of an affected individual may be offered genetic counselling to discuss inheritance patterns and testing options.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of GCH1-deficient DRD often begins with clinical observation of characteristic symptoms, particularly the diurnal fluctuation and initial good response to levodopa. Genetic testing for pathogenic variants in the GCH1 gene is the primary method to confirm the diagnosis [PMID:33678082].
In the UK, genetic testing for suspected GCH1-deficient DRD is available through the NHS Genomic Medicine Service (GMS). Referral to a clinical genetics service or specialist paediatric neurologist is typically made for diagnostic assessment. The relevant R-code for testing related to dystonia is R385. In some cases, biochemical tests, such as analysis of neurotransmitters in cerebrospinal fluid, may also be performed, though genetic testing is often definitive.
Management & lifestyle
The management of GCH1-deficient DRD primarily involves medication. The hallmark of treatment is low-dose levodopa, which is very effective in managing symptoms, often leading to dramatic improvements in movement and quality of life [PMID:16489370]. The dosage is carefully adjusted by a specialist to achieve optimal symptom control with minimal side effects.
Ongoing monitoring by a paediatric neurologist or movement disorder specialist is crucial to adjust medication as needed and address any evolving symptoms. While medication is highly effective, supportive therapies like physiotherapy or occupational therapy may be beneficial for some individuals, especially if diagnosis was delayed, to help with any residual movement difficulties or to manage secondary complications like muscle shortening.
UK care pathway
In the UK, individuals suspected of having GCH1-deficient DRD typically enter the NHS Genomic Medicine Service pathway. This generally involves referral by a GP or specialist (such as a paediatrician or neurologist) to a regional clinical genetics service. Genetic testing for the GCH1 gene (NHS R-code R385) can confirm the diagnosis.
Genetic counsellors are an integral part of this pathway, offering support and information to patients and their families about the genetic basis of the condition, inheritance patterns, and implications for other family members. Multidisciplinary teams, including neurologists, physiotherapists, and other specialists, work together to provide comprehensive care.
Frequently asked questions
What is the typical age of onset for Segawa disease?
Symptoms of Segawa disease typically begin in early childhood, often between one and ten years of age. However, in some cases, symptoms may appear later, even into adulthood.
How is Segawa disease treated?
Segawa disease is primarily treated with low-dose levodopa medication, which is highly effective in improving or even resolving symptoms of dystonia and other movement difficulties.
Will my children inherit Segawa disease?
Segawa disease is inherited in an autosomal dominant pattern. If you have the condition, each of your children has a 50% chance of inheriting the altered GCH1 gene and potentially developing symptoms.
Is Segawa disease a progressive condition?
Without treatment, the symptoms of Segawa disease can worsen over time. However, with timely and appropriate levodopa treatment, the condition is very well managed, and individuals can typically lead full and active lives without significant progression.
Can adults develop Segawa disease?
While Segawa disease typically presents in childhood, it can occasionally manifest later in life, sometimes referred to as adult-onset DRD. The diagnostic and treatment approaches remain similar regardless of the age of onset.